



PRESS RELEASE

AMOEBA signs a distribution agreement with DREWO

Third distribution agreement in Europe

Lyon (France), Rome, September 14th, 2017 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and wound care applications, announced today that it has signed a distribution agreement for its BIOMEBA product with DREWO. This agreement is pending marketing authorization (MA) in Italy.

The collaboration between DREWO and AMOEBA started in November 2015 with the signature of a Letter of Intention (LOI). In August 2016, both companies carried out a first field test in Italy for an industrial company in the automotive sector. This test, still ongoing today, has confirmed the effectiveness of BIOMEBA. Following this success, this car manufacturer wishes to start a new field test on another industrial site before the end of the year.

Meanwhile, a second test has started in January 2017 with a client of DREWO from the food industry.

DREWO is the third European distributor to express its confidence towards AMOEBA and its innovative technology through the signature of a distribution agreement.

"Italy is very sensitive to environmental issues, we are looking to offer green alternatives to our industrial customers. The BIOMEBA product, which we have tested its effectiveness on industrial sites, is the biological solution that we wish to offer to our customers." says **Ernesto LATINI, Chief Executive Officer of DREWO.**

"We are very pleased to strengthen the commercial relationship with DREWO through the signature of this distribution agreement. DREWO has a very extensive customer portfolio specialized in the industrial sector which represents a significant market for AMOEBA. " states **Fabrice PLASSON, Chief Executive Officer of AMOEBA.**



About DREWO:

Since 1990 DREWO offers its customers an integrated service covering several fields of expertise including chemical analysis and environmental impact studies for wastewater management systems. The company also carries out assessments of "legionella" risks in industrial cooling systems.

For more information: <http://www.drewo.it>



About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾ AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn⁽²⁾. Similarly, in a global wound care market estimated at EUR 15.2bn⁽³⁾, AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million⁽⁴⁾. The use of Willaertia magna C2c Maky in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on www.amoeba-biocide.com.

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

(3) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016

(4) BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

Contacts:

AMOEBA

Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

DREWO

Ernesto LATINI
Chief Executive Officer
Tel. : +39 06 9006511
ernesto.latini@drewo.it

ACTIFIN

Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr